Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907944 | 1.00 | MAPT (0.47) | MAPTFOLH1CPB1CPB2DPP8 | |
| SCHEMBL4904596 | 0.84 | EPHX2 (0.44) | — | |
| SCHEMBL4819898 | 0.81 | FOLH1 (0.49) | MAPTFOLH1CPB1CPB2DPP8 | |
| SCHEMBL4819908 | 0.81 | FOLH1 (0.49) | MAPTFOLH1CPB1CPB2DPP8 | |
| SCHEMBL14104857 | 0.81 | MAPT (0.58) | MAPTFOLH1 | |
| SCHEMBL4897016 | 0.81 | MMP3 (0.48) | MMP9 | |
| SCHEMBL4906479 | 0.78 | CTSS (0.45) | MMP9HTT | |
| SCHEMBL17646421 | 0.73 | FOLH1 (0.56) | MAPTFOLH1DPP8DPP7MMP9 | |
| SCHEMBL17646347 | 0.73 | FOLH1 (0.56) | MAPTFOLH1DPP8DPP7MMP9 | |
| SCHEMBL13251388 | 0.72 | HTT (0.65) | FOLH1CPB1CPB2DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | MAPT 3861/4885FOLH1 1390/4885CPB1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.